Twitter YouTube LinkedIn One of Alberta's Top 70 Employers Canada's Top Small & Medium Employers Best Workplaces Great Place To Work Uruguay 2023 award logo
  • Who We Are
    • Our Mission
    • Background
    • Team
    • Industry Collaborators
  • Why Us?
    • Investigator Network
    • Patient Advocacy and TRIO
    • Translational Research
    • Tissue Acquisition
  • Our Services
    • Clinical Start-up Unit (CSU)
    • Project Management
    • Monitoring Resources
    • Medical Operations
    • Drug Safety & Pharmacovigilance
    • Data Management
    • Biostatistics
    • Quality Assurance and Regulatory Affairs
    • TRIO-US Investigator Network
  • Studies & Results
  • News
  • Careers
  • Contact
Twitter YouTube LinkedIn One of Alberta's Top 70 Employers Canada's Top Small & Medium Employers Best Workplaces Great Place To Work Uruguay 2023 award logo

Nabholtz JM, Pienkowski T, Mackey J – 2002 – Phase III trial comparing TAC (docetaxel, doxorubi

By Jaskiran Mehta • January 10, 2018

Comments

Why TRIO™ Brochure Link to Intranet Transparence Disclaimer Privacy Policy (780) 702-0200 contact@trioncology.org
© 2011-2022 TRIO™ - Translational Research In Oncology